10x Genomics, Inc. - TXG STOCK NEWS

10x Genomics (TXG) plans to release its financial results for Q4 and full year 2022 on February 15, 2023, after market close. Management will host a conference call at 1:30 PM PT to discuss the results and provide insights on business developments and future outlook. The company's integrated solutions are essential in advancing biological research, with products utilized by top research institutions and pharmaceutical companies. The live webcast will be accessible on their website, with a replay available for at least 45 days.

10x Genomics, Inc. (Nasdaq: TXG), a leader in life sciences, will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California. Management is set to present on January 9 at 7:30 a.m. PT and participate in a panel on January 10 at 5:15 p.m. PT. The events can be accessed via a live and archived webcast on the company's Investors page. 10x Genomics specializes in products that analyze biological systems, with over 4,100 research citations and a robust patent portfolio.

10x Genomics (Nasdaq: TXG) has announced the commercial launch of the Xenium platform, enabling high-throughput in situ analysis of gene and protein expression at the subcellular level. The platform, which includes a versatile instrument and interactive software, allows researchers to explore complex biological data with high sensitivity. Key features include class-leading speed, broad gene panel compatibility, and intact tissue morphology compatibility. This launch signifies a notable advancement in biological analysis technology, aimed at answering critical research questions in fields like oncology and neurobiology.

10x Genomics (TXG) announced the commercial launch of BEAM (Barcode Enabled Antigen Mapping), a new solution aimed at accelerating antibody and T-cell receptor discovery. Built on the Chromium Single Cell Immune Profiling technology, BEAM allows comprehensive antigen screening, significantly improving therapeutic discovery timelines. The workflow is optimized for efficiency, taking only a week and promising robust data output. This marks the sixth major product launch from 10x Genomics in 2022, demonstrating the strength of its R&D pipeline, with shipping expected to begin in December 2022.

10x Genomics (Nasdaq: TXG) reported its third quarter 2022 financial results, revealing a revenue of $131.1 million, up 5% year-over-year and 14% quarter-over-quarter. The gross margin decreased to 77% from 80% due to increased costs and changes in product mix. Operating expenses surged 21% to $140.7 million, contributing to a significant operating loss of $40 million compared to $15.9 million last year. The net loss reached $41.9 million, widening from $17.2 million. 10x Genomics maintains its 2022 revenue guidance of $500 million to $520 million.

10x Genomics (Nasdaq: TXG) will host an Investor Day on December 8, 2022, at its headquarters in Pleasanton, CA, starting at 9:00 a.m. PT. The event will feature presentations from the leadership team and a Q&A session.

The live webcast will be accessible via the company's website, with an archive available for 45 days post-event. In-person attendance is limited and by invitation only. 10x Genomics specializes in life science technology, providing integrated solutions for biological analysis, with a strong presence in top research institutions worldwide.

10x Genomics (Nasdaq: TXG) will announce its third quarter 2022 financial results after market close on November 2, 2022. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, business developments, and future outlook. Investors can access the live audio on the company's website, with playback available for at least 45 days post-event. 10x Genomics provides advanced life science technology solutions for analyzing biological systems, with strong adoption among leading global research institutions and pharmaceutical companies.

10x Genomics (Nasdaq: TXG) announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 10:35 a.m. Eastern Time. The company will engage in a fireside chat, with a live and archived webcast available on its investors' webpage. 10x Genomics, a life sciences technology leader, focuses on products that enhance understanding of biological systems. Their solutions are widely adopted by top global research institutions and pharmaceutical companies, backed by over 1,500 patents and citations in over 3,800 research papers.

10x Genomics (NASDAQ: TXG) reported a 1% decrease in revenue for Q2 2022, totaling $114.6 million, down from $115.8 million in Q2 2021. Factors included decreased demand from China, logistics issues in Europe, and foreign exchange challenges. The gross margin fell to 76%, significantly down from 96% in the previous year. Operating expenses rose 24% to $150 million, with an operating loss of $63.1 million compared to $10.3 million last year. The company revised its 2022 revenue guidance to $500-$520 million, reflecting 2%-6% growth.